Table 2.
Clinical Characteristics of Cohort 2
| Variable | Patient Group (N = 17) | Control Group (N = 17) |
|---|---|---|
| Age (Years; Mean ± SD) | 70 (± 12.1) | 70 (± 7.2) |
| Sex [as % female] | 6 (35.3%) | 9 (52.9%) |
| BMI [Mean ± SD] | 28.4 (± 4.1) | 28.9 (5.5%) |
| Weight Categories | ||
| Obese [n (%)] | 6 (35.3%) | 5 (29.4%) |
| Overweight [n (%)] | 7 (41.2%) | 8 (47.1%) |
| Normal [n (%)] | 4 (23.5%) | 4 (23.5%) |
| Comorbidities | ||
| Hypertonia (n (%)) | 16 (94.1%) | 12 (70.6%) |
| Dyslipidemia (n (%)) | 9 (52.9%) | 9 (52.9%) |
| Diabetes mellitus (n (%)) | 3 (17.6%) | 6 (35.3%) |
| Stroke Characteristics | ||
| Etiology | ||
| Large-artery atherosclerosis | 3 (17.6) | NA$ |
| Cardioembolism [n (%)] | 9 (53.0) | NA$ |
| Stroke of other determined etiology [n (%)] | 2 (11.8) | NA$ |
| Stroke of undetermined etiology [n (%)] | 3 (52.9) | NA$ |
| NIHSS score (Median (IQR)) | 12 (6) | NA$ |
| Treatment ((n (%))& | 15 (88.2% | NA$ |
| Systemic thrombolysis (n (%))& | 13 (76.5%) | NA$ |
| Mechanical thrombolysis (n (%))& | 7 (41.2%) | NA$ |
| Combined treatment (n (%))& | 5 (29.4%) | NA$ |
| Stroke size, cm3 (Mean ± Std)* | 83.3 (± 59.3) | NA$ |
For the assessment of monocyte and granulocyte subpopulations, a second cohort of 17 stroke patients and 17 control patients was analyzed on admission and on days 1, 3, and 5 thereafter. This cohort was recruited from 2017-2018. & The numbers of systemic thrombolysis procedures and mechanical thrombectomies are the total number of patients receiving the treatments and include patients receiving a combination of both. *only for 8 patients MRI data for measurement of stroke size were available. $NA: Not applicable. SD: standard deviation